Tanios Bekaii-Saab, MD, FACP

Tanios Bekaii-Saab, MD, FACP, discusses the evolution of treatment for patients with KRAS G12C–mutant and HER2-overexpressing colorectal cancer.

Tanios S. Bekaii-Saab, MD, offers closing thoughts on the unmet needs and future of HER2+ metastatic colorectal cancer treatment.

An overview of the DESTINY-CRC02 study, which looked at trastuzumab deruxtecan in patients with HER2+ metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, discusses recent clinical trials and provides insights on the evolving metastatic colorectal cancer treatment landscape.

An expert on colorectal cancer discusses the relationship between HER2 status and treatment selection and response.

Tanios S. Bekaii-Saab, MD, gives an overview of the presentation trends and molecular testing practices for metastatic colorectal cancer.

Dr Tanios S. Bekaii-Saab closes the discussion with key unmet needs in the mCRC treatment landscape.

Discussion centered around emerging treatment options for patients with HER2+ mCRC, including trastuzumab deruxtucan.

Clinical insights regarding the design, patient population, and overall aims of the ongoing phase 3 clinical trial MOUNTAINEER-03.

An expert in gastrointestinal cancers reviews outcomes from the MOUNTAINEER clinical trial, focusing on concordance analysis data for HER2 testing as well as the efficacy of tucatinib and trastuzumab.

Tanios S. Bekaii-Saab, MD, FACP introduces the metastatic colorectal cancer (mCRC) treatment landscape and the emphasizes importance of biomarker testing in patients with mCRC.

Tanios S. Bekaii-Saab, MD shares his perspective on exciting breakthroughs in GI malignancy research and treatment, focusing on HER2, BRAF V600E, and KRAS g12c.

Subject matter expert discusses the impetus for and data from the MOUNTAINEER trial, touching on patient populations, study design, and key efficacy and safety endpoints.

An experienced oncologist discusses the role of HER2 in GI malignancies and the applicability of the existing body of research concerning HER2 in breast cancer.

Tanios S. Bekaii-Saab, MD describes recent progress in the metastatic colorectal cancer treatment landscape and raises key questions concerning the future of the field.

Tanios S. Bekaii-Saab, MD, FACP, discusses the updated results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C-mutated gastrointestinal cancers, including pancreatic ductal adenocarcinoma.

Tanios S. Bekaii-Saab, MD, FACP, discusses the promise of non–VEGF inhibitor platforms in hepatocellular carcinoma.

Tanios S. Bekaii-Saab, MD, FACP, discusses the addition of bevacizumab to trifluridine/tipiracil in patients with metastatic colorectal cancer

Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses incorporating potential mechanisms of resistance into treatment selection in hepatocellular carcinoma.

Tanios S. Bekaii-Saab, MD, FACP, discusses second-line treatment options in hepatocellular carcinoma.

Dr. Tanios Bekaii-Saab spent time discussing the path to practicing in gastrointestinal malignancies, how he navigates balancing his professional and personal life, and mottos he has lived by throughout his career and while caring for his patients.

Tanios Bekaii-Saab, MD, FACP, discusses the clinical implications of the results of the phase III POLO trial in metastatic pancreatic cancer.